Тёмный

SGLT-2 I, Natriuresis & Aquaresis: DAPA Shuttle-1 - Dr. A. Marton and Prof. Dr. J. Titze (Singapore) 

MARKUS at HOMe
Подписаться 4,6 тыс.
Просмотров 487
50% 1

Dr. Adriana Marton and Prof. Dr. Jens Titze explain how SGLT-2 Inhibitors will affect natriuresis and aquaresis in patients with heart failure, based upon their DAPA Shuttle-1 study, which has been published few weeks ago in Journal of the American College of Cardiology.
Dr. Adriana Marton and Prof. Dr. Jens Titze are nephrologists at Duke-NUS Medical School in Singapore and global leaders in the field of physiologic and pathophysiologic sodium and water handling in humans.
The interview was recorded on June 26th, 2024.
Moderators: Prof. Dr. David M. Leistner and Prof. Dr. Gunnar Heine (both Frankfurt, Germany).
Articles discussed:
Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure.
Marton A, Saffari SE, Rauh M, Sun RN, Nagel AM, Linz P, Lim TT, Takase-Minegishi K, Pajarillaga A, Saw S, Morisawa N, Yam WK, Minegishi S, Totman JJ, Teo S, Teo LLY, Ng CT, Kitada K, Wild J, Kovalik JP, Luft FC, Greasley PJ, Chin CWL, Sim DKL, Titze J.
J Am Coll Cardiol 2024
doi: 10.1016/j.jacc.2024.02.020
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
Jackson AM, Dewan P, Anand IS, Bělohlávek J, Bengtsson O, de Boer RA, Böhm M, Boulton DW, Chopra VK, DeMets DL, Docherty KF, Dukát A, Greasley PJ, Howlett JG, Inzucchi SE, Katova T, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Ljungman CEA, Martinez FA, O'Meara E, Sabatine MS, Sjöstrand M, Solomon SD, Tereshchenko S, Verma S, Jhund PS, McMurray JJV
Circulation 2020
doi: 10.1161/CIRCULATIONAHA.120.047077
Magnetic resonance-determined sodium removal from tissue stores in hemodialysis patients.
Dahlmann A, Dörfelt K, Eicher F, Linz P, Kopp C, Mössinger I, Horn S, Büschges-Seraphin B, Wabel P, Hammon M, Cavallaro A, Eckardt KU, Kotanko P, Levin NW, Johannes B, Uder M, Luft FC, Müller DN, Titze JM
Kidney Int 2015
doi: 10.1038/ki.2014.269
Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.
Sen T, Scholtes R, Greasley PJ, Cherney DZI, Dekkers CCJ, Vervloet M, Danser AHJ, Barbour SJ, Karlsson C, Hammarstedt A, Li Q, Laverman GD, Bjornstad P, van Raalte DH, Heerspink HJL.
Diabetes Obes Metab 2022
doi: 10.1111/dom.14729
Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide.
Powles J, Fahimi S, Micha R, Khatibzadeh S, Shi P, Ezzati M, Engell RE, Lim SS, Danaei G, Mozaffarian D; Global Burden of Diseases Nutrition and Chronic Diseases Expert Group (NutriCoDE)
BMJ Open 2013
doi: 10.1136/bmjopen-2013-003733
Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation.
Marton A, Kaneko T, Kovalik JP, Yasui A, Nishiyama A, Kitada K, Titze J
Nat Rev Nephrol 2021
doi: 10.1038/s41581-020-00350-x
Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).
Schulze PC, Bogoviku J, Westphal J, Aftanski P, Haertel F, Grund S, von Haehling S, Schumacher U, Möbius-Winkler S, Busch M
Circulation 2022
doi: 10.1161/CIRCULATIONAHA.122.059038

Опубликовано:

 

15 сен 2024

Поделиться:

Ссылка:

Скачать:

Готовим ссылку...

Добавить в:

Мой плейлист
Посмотреть позже
Комментарии    
Далее
SGLT2 Inhibitors in Chronic Kidney Disease
9:06
Просмотров 20 тыс.
Post ESC 2024
2:09:50
Просмотров 1,1 тыс.
Coronary Artery Disease | Clinical Medicine
52:22
Просмотров 115 тыс.